| Literature DB >> 21248260 |
Fabienne Andris1, Sébastien Denanglaire, Erika Baus, Anthony Rongvaux, Jonathan Steuve, Richard A Flavell, Oberdan Leo.
Abstract
Adjuvant formulations boost humoral responses by acting through several, yet incompletely elucidated pathways. In this study, we show that oligomycin or 5-aminoimidazole-4-carboxamide-1-β-D-ribonucleoside (AICAR) enhances Ab production when coinjected with T cell-dependent Ags. Oligomycin and AICAR lead to intracellular ATP reduction, suggesting that metabolic stress could be sensed by immune cells and leads to increased humoral responses. AICAR promotes IL-4 and IL-21 by naive Th cells but does not affect dendritic cell activation/maturation in vitro or in vivo. Accordingly, the adjuvant effect of AICAR or oligomycin does not require MyD88 or caspase-1 expression in vivo. Because AICAR is well tolerated in humans, this compound could represent a novel and safe adjuvant promoting humoral responses in vivo with a minimal reactogenicity.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21248260 DOI: 10.4049/jimmunol.1002333
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422